Case Report

Pseudothrombocytopenia induced by EDTA and chronic inflammatory demyelinating polyneuropathy

Edgar Carvajal-Vega¹, Juan I. Padilla-Cuadra¹,³, Jorge López-Villegas², María del Milagro Mata-Sánchez²

Abstract

Ethylendiaminetetraacetic acid is an anticoagulant widely used in health sciences in the processing of medical samples. Given that, in the presence of certain immune conditions, this agent can induce a false low platelet count (pseudothrombocytopenia), it must be considered as part of the differential diagnosis for thrombocytopenia. The case presented is about a 68 year old patient with severe thrombocytopenia with no clinical evidence of bleeding, which was later demonstrated as pseudothrombocytopenia induced by EDTA. The presence of a false thrombocytopenia was demonstrated adding amikacin to the blood sample.

Keywords: Thrombocytopenia, EDTA.

Date received: January 4, 2016 Date of approval: February 18, 2016

Thrombocytopenia is a common finding in critically ill patients. This drive the need to perform laboratory studies to clarify its cause. It should be added that the presence of a low platelet count involves a more complex management of the patient in principle because of the increased risk of bleeding. Besides the real causes of thrombocytopenia, there are conditions or laboratory artifacts that can cause falsely low platelet counts and induce unnecessary studies. One such cause of pseudothrombocytopenia is the anticoagulant Ethylendiaminetetraacetic acid (EDTA) used for handling blood samples.

The pseudothrombocytopenia due to Ethylendiaminetetraacetic acid (PT-EDTA) is a recognized phenomenon that occurs frequently and must be differentiated from true thrombocytopenia, in order to avoid additional studies or even to avoid the patient to receive unnecessary platelet transfusions. A case due to this entity is reported in a patient admitted to the Neurocritical Care Unit with the diagnosis of chronic inflammatory demyelinating polyneuropathy for apheresis therapy.

Case Report

A 68 year old patient with personal history of chronic inflammatory demyelinating newly diagnosed, who debuted about four weeks ago with ascending weakness and sensory disturbances is presented. He was treated with a single dose of intravenous gammaglobulin and regained his functional capacity. He is readmitted due to an exacerbation, probably triggered by acute diarrhea.

At the admission to the Neurocritical Unit he was thermodynamically stable, with a vital capacity of 50 cc / kg, and shows distress. He also had a decreased sensitivity and muscular strength in distal extremities, with inability to overcome gravity and horizontal displacement movements were preserved. Since was reported thrombocytopenic with a platelet count of 56,000 / mm³, and a description in the blood smear the read “platelet clumps”. On the second day of admission a central internal jugular line catheter was punctured unsatisfactory, and right carotid was canalized by mistake, it drew attention that although 5000 platelets were documented in the blood analysis, the patient did not develop expansive hematoma or procedure-related bleeding. A left internal jugular central line was placed with a catheter for apheresis. Therefore, pseudothrombocytopenia was suspected and it was decided to try other anticoagulants and amikacin in the sample, which has been shown to reverse the anticoagulant induced pseudothrombocytopenia. Platelet determination is made with EDTA, citrate and amikacin tubes. An important platelet aggregation is
noted in the sample containing EDTA and the dispersion of platelets increases as there is a change to citrate, in which lumps disappear with the use of aminoglycoside (Figure 1). With the same sample it is determined that there are changes in the smear and changes in platelet count (11,000 / mm$^3$ with EDTA to 91,000 / mm$^3$ with amikacin) (Figure 2).

Plasmapheresis with albumin therapy is initiated. The patient develops a nosocomial lung infection with acute respiratory distress; he requires intubation and management with high-dose vasopressors. HE progresses to refractory septic shock and finally dies.

**Discussion**

The case illustrates how the incongruity between clinical and laboratory findings (absence of bleeding despite arterial puncture in the presence of a supposed thrombocytopenia), makes the suspicion of an artifact due to laboratory-induced anticoagulant in the sample.

The PT-EDTA was initially described in 1969 by Gowland. In 1970, Watkins and Shulman describe a binding factor in the presence of this anticoagulant at low temperatures. There is a widespread use of this anticoagulant for sample handling because of the advantage that it does not distort cell morphology. The phenomenon of induced pseudothrombocytopenia is an artifact resulting from the presence of agglutinating anti platelet antibodies. The production of platelet clumps causes automatic cell counting systems to provide a falsely low platelet level. In addition, the device misinterprets these lumps as “lymphocytes”. Although it is described primarily in associated to EDTA, it can also occur in blood with heparin or citrate.

The estimated prevalence is 0.1 to 2% in hospitalized patients and 15-17% in out-patients. The antibodies described are primarily IgG, although there may be mixtures of IgA, IgM that precipitates at low temperatures. Although considered an in vitro phenomenon without clinical relevance, Fukuda Ohashi et al., reported that the presence of the phenomenon could
be associated with increased mortality and malignancy.\textsuperscript{14} It is presumed that the membrane glycoprotein IIB is the site for protein coupling of EDTA-dependent antibody on the platelet membrane. Glycoprotein IIB exists alongside IIIa glycoprotein, as a heterodimer dependent of calcium. It is theorized that the dimer dissociates when the concentration of calcium decreases and it re-associates when the availability of the ion increases (Figure 3). The anti-platelet antibody epitope that causes EDTA pseudothrombocytopenia is a cryptoantigen that is only revealed when the IIb glycoprotein dissociates.\textsuperscript{17}

By this mechanism it is assumed that EDTA, when calcium concentration decreases, it allows the exposure of the binding site of the antibody and the clumping of platelets. In fact, Hyojin et al., achieved to dissociate the platelets upon introduction of calcium chloride in the samples \textit{in vitro}.\textsuperscript{17} Recent research have clarified the type of reaction. Lippi et al. describe that autoantibodies react optimally between 0 and 4 degrees Celsius, and after binding with glycoprotein, the expression or activation of antigen the expression of several proteins is stimulated: CD62P, known as protein granulation membrane 140 or GMP140, CD63 known as lysosomal glycoprotein gp55 or type III, and thrombospondin. In the end, this triggers the tyrosine kinase, which brings together groups and platelets, reducing their count.\textsuperscript{18}

Although the presence of an autoimmune disease in the patient could relate to production of antibodies involved in this phenomenon, it was not possible to determine the platelet agglutination due to an specific antibody.

The diagnosis of this condition is established; the first key is the clinical suspicion where the platelet count and the clinic manifestations do not correspond. Suspicin increases if the report includes clumps of platelets, as illustrated in this case. Conditions surrounding the sampling are also important, which is included in the major diagnostic criteria\textsuperscript{18} (Table 1).

They have recognized several actions to avoid this artifact, including heating the sample to 37 C, neutralization with sodium citrate, or use heparin lithium, ammonium oxalate, theoline, trisodium citrate and addition of aminoglucoside.\textsuperscript{18} As demonstrated in this case, the disaggregation of the platelet clumps can be achieved by adding amikacin. The mechanism involved in this effect is unknown.\textsuperscript{19}

The differential diagnosis of pseudothrombocytopenia includes causes as defects in the collection process, exposure to drugs (valproate, olanzapine, abciximab) and giant platelet syndrome. The main recommendation to avoid this phenomenon is to analyze the sample almost immediately, or to use other anticoagulants. It has also tried to reverse it by using substances such as teoline.\textsuperscript{15} Since aminoglycosides reverse this platelet clumping, it should be considered a tool to distinguish a real thrombocytopenia pseudothrombocytopenia by this mechanism.\textsuperscript{16}

In conclusion, the PT-EDTA should be recognized as an artifact and does not require other diagnostic studies or unnecessary transfusions. Its recognition can be assisted by a simple method, such as addition of amikacin to sample, to reverse platelet clumping. This case shows the importance of the clinical suspicion of the presence of this artifact and to discard true thrombocytopenia.

<table>
<thead>
<tr>
<th>Table 1: Major diagnostic criteria for Pseudothrombocytopenia induced by EDTA</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Platelet count less than 100.000</td>
</tr>
<tr>
<td>2. Use of tubes for samples containing exclusively EDTA at room temperature</td>
</tr>
<tr>
<td>3. Time of arrival of the samples to the laboratory</td>
</tr>
<tr>
<td>4. Presence of clumps or platelet aggregations in the tubes of samples with EDTA</td>
</tr>
<tr>
<td>5. No relation between the signs and symptoms related with low platelet counts.</td>
</tr>
</tbody>
</table>

Adapted form Reference 18
References


